重组人红细胞生成素联合铁剂治疗在初次髋、膝关节置换术贫血患者中的有效性及安全性分析  

Effect and Safety Analysis of Recombinant Human Erythropoiesis Combined with Ferralia for Anemia Patients with Primary Hip and Knee Joint Replacement

作　　者：韩天江 朱宗龙 王继雄 HAN Tianjiang;ZHU Zonglong;WANG Jixiong(Lanzhou City Xigu District Hospital of Traditional Chinese Medicine,Lanzhou,Gansu 730060)

机构地区：[1]兰州市西固区中医院,甘肃兰州730060

出　　处：《智慧健康》2023年第16期161-164,共4页Smart Healthcare

摘　　要：目的探究在初次髋、膝关节置换术贫血患者治疗中应用重组人红细胞生成素联合铁剂治疗的临床疗效,分析其安全性。方法选取2019年3月-2021年4月来院治疗的初次髋、膝关节置换术贫血患者72例,依据电脑随机数字表法将其分为观察组和对照组,每组36例。对照组行氨甲环酸治疗,观察组行重组人红细胞生成素联合铁剂治疗,对比两组治疗效果。结果术前两组患者血红蛋白水平比较,无统计学意义(P>0.05);术后第1d、3d、5d,观察组状况更佳(P<0.05);于并发症总发生率数据比较中,观察组远低于对照组(P<0.05);两组患者在术前等待时间比较中,差异不显著(P>0.05);而在术中输血率、术后住院时间等数据比较中,观察组更具优势(P<0.05);在生活质量比较中,治疗前,两组患者生活质量差异不显著(P>0.05);治疗后,观察组更优(P<0.05)。结论对初次髋、膝关节置换术贫血患者进行术前重组人红细胞生成素联合铁剂治疗,可有效改善患者的贫血症状,促进其术后恢复,且术后并发症较少,安全性较好,提高了患者的生活质量,值得应用。Objective To explore clinical effect and safety of recombinant human erythropoiesis combined with ferralia in treatment of anemia patients with primary hip and knee Joint replacement.Methods The paper chose 72 anemia patients with first hip and knee Joint replacement from March 2019 to April 2021 as study subjects,and divided them into group with computer random number table method,treated with tranexamic acid,recombinant human erythropoiesis and ferralia respectively.Treatment effect was compared.Results Before surgery,there was no statistically significant difference in hemoglobin levels between two groups(P>0.05).On the 1st,3rd and 5th day after surgery,observation group showed better condition,i.e.P<0.05.Total incidence rate of complications of observation group was 5.56%,much lower than 25.00%of control group,P<0.05;there was no significant difference in preoperative waiting time between two groups,P>0.05.Observation group had more advantages in data such as intraoperative blood transfusion rate and postoperative hospital stay,P<0.05.Before treatment,there was no significant difference in life quality between two groups,P>0.05.After treatment,life quality of observation group was better,P<0.05.Conclusion Recombinant human erythropoiesis combined with ferralia can improve anemia symptoms of anemia patients after initial hip and knee Joint replacement effectively,promote postoperative recovery,and improve life quality of patients,with fewer postoperative complications,better safety,which is worthy of application.

关 键 词：重组人红细胞生成素 铁剂 髋、膝关节置换术 贫血 安全性 临床疗效 

分 类 号：R687.4[医药卫生—骨科学] R556[医药卫生—外科学]